Wilkins I A, Lynch L, Mehalek K E, Berkowitz G S, Berkowitz R L
Department of Obstetrics, Gynecology and Reproductive Science, Mount Sinai Medical Center, New York, NY 10029.
Am J Obstet Gynecol. 1988 Sep;159(3):685-9. doi: 10.1016/s0002-9378(88)80035-8.
Ritodrine as the first-line drug in the treatment of established preterm labor has been supplanted in some centers by magnesium sulfate. To assess the relative efficacy and rates of side effects of these two agents, 120 patients were randomly assigned to receive one of these two drugs. Patients were included if they had intact membranes and met strict criteria for the definition of labor. In both groups excellent outcome was achieved, with 96.3% and 92.3% of patients receiving ritodrine and magnesium sulfate, respectively, obtaining a delay in delivery of greater than 48 hours. Side effects were comparable in both groups, although they tended to be more serious in the patients receiving ritodrine. In patients receiving both drugs together, the rate of side effects was 77% without a demonstrable benefit over a single agent. We conclude that ritodrine and magnesium sulfate are tocolytics of comparable efficacy and when used aggressively are highly successful in delaying delivery.
利托君作为治疗已确诊早产的一线药物，在一些中心已被硫酸镁所取代。为评估这两种药物的相对疗效和副作用发生率，120例患者被随机分配接受这两种药物中的一种。如果患者胎膜完整且符合严格的分娩定义标准，则纳入研究。两组均取得了良好的结果，接受利托君和硫酸镁治疗的患者分别有96.3%和92.3%的分娩延迟超过48小时。两组的副作用相当，尽管接受利托君治疗的患者副作用往往更严重。同时接受两种药物治疗的患者，副作用发生率为77%，与单一药物相比并无明显益处。我们得出结论，利托君和硫酸镁是疗效相当的宫缩抑制剂，积极使用时在延迟分娩方面非常成功。
